Monograph
C09AA06 - Quinapril |
Not porphyrinogenic |
NP |
Rationale
No evidence of CYP-dependent metabolism.
Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea, dyspepsia, and abdominal pain motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
HCl-salt of quinapril, which is a prodrug to the metabolite quinaprilate, which is excreted unchanged by the kidneys.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, diarrhoea, dyspepsia, and abdominal pain. Other common side effects are back pain, myalgia, chest pain, fatigue and asthenia.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025